These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 28352306)

  • 1. Risk of cardiovascular disease in inflammatory bowel disease.
    Wu P; Jia F; Zhang B; Zhang P
    Exp Ther Med; 2017 Feb; 13(2):395-400. PubMed ID: 28352306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammatory bowel disease and cardiovascular diseases: a concise review.
    Wu H; Hu T; Hao H; Hill MA; Xu C; Liu Z
    Eur Heart J Open; 2022 Jan; 2(1):oeab029. PubMed ID: 35919661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ischemic Heart Disease in Patients with Inflammatory Bowel Disease: Risk Factors, Mechanisms and Prevention.
    Jucan AE; Gavrilescu O; Dranga M; Popa IV; Mihai BM; Prelipcean CC; Mihai C
    Life (Basel); 2022 Jul; 12(8):. PubMed ID: 35892915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammatory bowel disease and the risk for cardiovascular disease: Does all inflammation lead to heart disease?
    Bigeh A; Sanchez A; Maestas C; Gulati M
    Trends Cardiovasc Med; 2020 Nov; 30(8):463-469. PubMed ID: 31653485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The oft-overlooked cardiovascular complications of inflammatory bowel disease.
    Massironi S; Mulinacci G; Gallo C; Viganò C; Fichera M; Villatore A; Peretto G; Danese S
    Expert Rev Clin Immunol; 2023 Apr; 19(4):375-391. PubMed ID: 36722283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thromboembolic and atherosclerotic cardiovascular events in inflammatory bowel disease: epidemiology, pathogenesis and clinical management.
    Sleutjes JAM; van Lennep JER; van der Woude CJ; de Vries AC
    Therap Adv Gastroenterol; 2021; 14():17562848211032126. PubMed ID: 34377149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologic therapy for inflammatory bowel disease.
    Ardizzone S; Bianchi Porro G
    Drugs; 2005; 65(16):2253-86. PubMed ID: 16266194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of cardiovascular disease in inflammatory bowel disease.
    Andersen NN; Jess T
    World J Gastrointest Pathophysiol; 2014 Aug; 5(3):359-65. PubMed ID: 25133036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What Links an Increased Cardiovascular Risk and Inflammatory Bowel Disease? A Narrative Review.
    Łykowska-Szuber L; Rychter AM; Dudek M; Ratajczak AE; Szymczak-Tomczak A; Zawada A; Eder P; Lesiak M; Dobrowolska A; Krela-Kaźmierczak I
    Nutrients; 2021 Jul; 13(8):. PubMed ID: 34444821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxidative stress and thromboxane-dependent platelet activation in inflammatory bowel disease: effects of anti-TNF-α treatment.
    Di Sabatino A; Santilli F; Guerci M; Simeone P; Ardizzone S; Massari A; Giuffrida P; Tripaldi R; Malara A; Liani R; Gurini E; Aronico N; Balduini A; Corazza GR; Davì G
    Thromb Haemost; 2016 Aug; 116(3):486-95. PubMed ID: 27305860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular Comorbidities and Inflammatory Bowel Disease: Causes and Consequences.
    Sinh P; Cross RK
    Gastroenterol Hepatol (N Y); 2024 Apr; 20(4):204-215. PubMed ID: 38682122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease: a nationwide series.
    Toussirot É; Houvenagel É; Goëb V; Fouache D; Martin A; Le Dantec P; Dernis E; Wendling D; Ansemant T; Berthelot JM; Bader-Meunier B; Kantelip B;
    Joint Bone Spine; 2012 Oct; 79(5):457-63. PubMed ID: 22088934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opposite effects of interferon regulatory factor 1 and osteopontin on the apoptosis of epithelial cells induced by TNF-α in inflammatory bowel disease.
    Tang R; Yang G; Zhang S; Wu C; Chen M
    Inflamm Bowel Dis; 2014 Nov; 20(11):1950-61. PubMed ID: 25208103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allergic and Immunologic Perspectives of Inflammatory Bowel Disease.
    Clarke K; Chintanaboina J
    Clin Rev Allergy Immunol; 2019 Oct; 57(2):179-193. PubMed ID: 29754190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The risk of cardiovascular complications in inflammatory bowel disease.
    Czubkowski P; Osiecki M; Szymańska E; Kierkuś J
    Clin Exp Med; 2020 Nov; 20(4):481-491. PubMed ID: 32785793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arterial structure and function in inflammatory bowel disease.
    Zanoli L; Rastelli S; Inserra G; Castellino P
    World J Gastroenterol; 2015 Oct; 21(40):11304-11. PubMed ID: 26523102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular disease: extraintestinal manifestation of inflammatory bowel disease.
    Lakhanpal S; Aggarwal K; Kaur H; Kanwar K; Gupta V; Bhavsar J; Jain R
    Intest Res; 2024 May; ():. PubMed ID: 38712363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is there a cardiovascular risk in inflammatory bowel diseases?
    Mitu O; Alexandrescu DM; Cătălina M; Cristina CP
    Rev Med Chir Soc Med Nat Iasi; 2014; 118(4):918-23. PubMed ID: 25581948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.